Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 12/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16690101 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2521573 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2549985 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL30208193 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL16081101 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2510991 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2512431 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL850195 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2510990 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL19821287 | 0.95 | BTN3A1 (0.47) | BTN3A1CYP3A4CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES INC (US) | 2025-02-20 | — | — | US | claimed |
| EP-2609923-B1 | PROCESS FOR THE CRYSTALLISATION OF (S)-ISOPROPYL 2-(((S)-(PERFLUOROPHENOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE | GILEAD PHARMASSET LLC (US) | 2017-05-24 | — | — | EP | claimed |
| EP-2609923-A2 | Nucleoside Phosphoramidates | Gilead Pharmasset LLC (US) | 2013-07-03 | — | — | EP | claimed |
| EP-2552930-A2 | NUCLEOSIDE PHOSPHORAMIDATES | Gilead Pharmasset LLC (US) | 2013-02-06 | — | — | EP | claimed |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-13 | — | — | US | claimed |
| WO-2011123645-A2 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | claimed |
| US-12551499-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667053-A2 | BETA-D-2'-DEOXY-2'ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | ATEA Pharmaceuticals, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-3265102-B1 | BETA-D-2'-DEOXY-2'ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | ATEA PHARMACEUTICALS INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250243235-A1 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6- SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| EP-3897668-B1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA PHARMACEUTICALS INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES INC (US) | 2025-02-20 | — | — | US | disclosed |
| US-12084473-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20130288997-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES, INC. | 2013-10-31 | — | — | US | disclosed |
| US-20130288997-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES, INC. | 2013-10-31 | — | — | US | disclosed |
| EP-2609923-A2 | Nucleoside Phosphoramidates | Gilead Pharmasset LLC (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2552930-A2 | NUCLEOSIDE PHOSPHORAMIDATES | Gilead Pharmasset LLC (US) | 2013-02-06 | — | — | EP | disclosed |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011123645-A2 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | BTN3A1 3601/4885CYP3A4 3916/4885CYP2C9 4098/4885 |
| US-12084473-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | BTN3A1 4024/4885CYP3A4 3228/4885CYP2C9 3652/4885 |
| US-20130288997-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | BTN3A1 3601/4885CYP3A4 3916/4885CYP2C9 4098/4885 |
| US-12551499-B2 | Highly active compounds against COVID-19 | PNP, SLC29A2, MTAP | BTN3A1 4840/4885CYP3A4 530/4885CYP2C9 323/4885 |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | BTN3A1 3601/4885CYP3A4 3916/4885CYP2C9 4098/4885 |
| US-20250243235-A1 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6- SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | BTN3A1 3943/4885CYP3A4 3614/4885CYP2C9 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.